Ferring pharmaceuticals completes phase III study of degarelix in prostate cancer patients
Superior remission rates for once daily use of Pentasa® (mesalazine) in ulcerative colitis
Ferring Pharmaceuticals Forges Worldwide Licensing Agreement for Budesonide MMX™
Ferring Pharmaceuticals Announces Board Changes
New data demonstrates both cost and efficacy benefit of MENOPUR® compared to recombinant FSH treatment
Inequality in treatment access remains a key issue for infertile couples across Europe
Ferring International Center S.A.Ch. de la Vergognausaz 50CH-1162 Saint-PrexSwitzerlandTel: +41 58 301 00 00Fax: +41 58 301 00 10
Email for media enquiries only.For other queries, please see our Contact page.
FERRING INTERNATIONAL CENTER S.A.CH. DE LA VERGOGNAUSAZ 50 1162 SAINT-PREXSWITZERLAND
TEL: +41 58 301 00 00FAX: +41 58 301 00 10
This global corporate website provides general information about the global Ferring Group. For information about Ferring or its products in a specific country, please select your country in the Global Locator. FERRING, the FERRING PHARMACEUTICALS logo and other Ferring product trade names are trademarks of Ferring B.V. save where indicated otherwise. ©2017 Ferring B.V.